Physician profile
Robert J Sommer
NPI 1316954514
$82,171.17
in general payments reported to CMS, 2019-2025
10 companies · $7,797 in 2025
The $7,797 reported for 2025 was more than what 95% of Adult Congenital Heart Disease providers received nationally (typical 2025 total: $272).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $10K · 2021: $15K · 2022: $31K · 2023: $16K · 2024: $1,664 · 2025: $7,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Travel and Lodging: $2,848 · Food and Beverage: $2,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,365.00 |
| Travel and Lodging | $2,848.27 |
| Food and Beverage | $2,034.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $67,662.98 | 2019-2025 | Gore Cardioform Septal Occluder, Gore Septal Occluder |
| Abbott Laboratories | $7,904.30 | 2019-2025 | Amplatzer Talisman, Amplatzer, Amplatzer Amulet |
| Boston Scientific Corporation | $5,196.30 | 2019-2024 | Watchman, Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Biosense Webster, INC. | $1,196.13 | 2024 | Thermocool Sf |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.81 | 2024-2025 | Jardiance |
| Pfizer INC. | $38.41 | 2025 | |
| Heartflow, INC. | $23.53 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $18.33 | 2024 | Arcalyst |
| Amgen INC. | $17.38 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sommer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.